The IBD Evidence Shift: Five Real-World Studies That Change What Life Sciences Teams Know

Key Takeaways

• Five studies by independent researchers using the TriNetX LIVE™ platform have delivered population-scale answers to the IBD evidence questions that have most directly constrained clinical, regulatory, and commercial decision-making across life sciences teams. 
• Each finding is immediately actionable: a safety submission strengthened, a formulary argument made, a surveillance gap closed, a new patient population unlocked, a long-debated prescribing concern resolved. 
• Together, these studies demonstrate what connected, longitudinal, population-scale RWD make possible, and why the most consequential IBD evidence is now being generated outside of controlled trials. 

The evidence environment for inflammatory bowel disease (IBD) has changed. Life sciences teams making decisions across safety submissions, formulary positioning, post-surgical surveillance, label expansion, and prescribing guidance are no longer waiting for the next trial to close. They are drawing on real-world data (RWD) generated at a scale and resolution that trials were never designed to match. 

Five studies conducted utilizing the TriNetX LIVE™ platform make that shift concrete. Each one answers a question that has been shaping clinical practice, regulatory strategy, and commercial decision-making in IBD, and each one required a dataset that no single site, registry, or trial could assemble. 

Does my IL-17 inhibitor create IBD risk?

For medical affairs, regulatory, and safety teams

IL-17 inhibitors are effective for psoriasis and ankylosing spondylitis. They are also, according to a propensity-matched analysis of 26,432 patients, associated with increased new-onset IBD risk compared with apremilast. In the matched cohort, incident IBD was rare, occurring in 1.07% of IL-17 inhibitor users versus 0.45% of apremilast users, an adjusted hazard ratio of 2.50. The risk is stronger for Crohn’s disease than ulcerative colitis (aHR 3.95 vs. 1.78), higher in adults over 60, and differentiated by agent: secukinumab showed a significant association; ixekizumab did not reach statistical significance. 

For medical affairs and regulatory teams, the strategic implication is direct. This is post-market safety monitoring that informs prescribing guidance, strengthens safety submissions, and shapes monitoring protocols for at-risk patient subgroups. 

Which second-line therapy should follow TNFi failure?

For commercial, market access, and Health Economics and Outcomes Research (HEOR) teams

Treatment sequencing after TNFi failure is one of the most actively contested decisions in ulcerative colitis management. A retrospective cohort study of 2,141 TNFi-experienced ulcerative colitis patients delivered head-to-head comparative data that no single-site dataset could support. 

Ustekinumab outperformed both vedolizumab and tofacitinib on composite efficacy and durability outcomes. Tofacitinib carried the lowest IV steroid use but the highest colectomy risk (aOR 2.63 vs. ustekinumab), and its two-year therapy discontinuation rate was 19.5% compared with 7.1% for ustekinumab. For formulary positioning, value dossiers, and payer engagement, this is the comparative sequencing evidence that moves decisions forward. 

Does terminal ileum resection increase cancer risk?

For HEOR teams

Surgery does not end the clinical risk calculus for Crohn’s disease patients. A propensity-matched cohort of 27,234 patients found that terminal ileum resection was associated with a 2.58-fold increase in colorectal cancer risk. The risk persisted regardless of colonic disease involvement (aHR 2.57 with colonic involvement; aHR 3.04 without), and biologic therapy showed no protective effect. The finding has direct clinical implications, and more nuanced research is needed to put these results in fuller context. 

The mechanism proposed in the study centers on altered bile acid metabolism: the terminal ileum is central to bile acid reabsorption, and its removal increases bile acid exposure in the colon, contributing to epithelial injury, inflammation, and tumorigenesis. For HEOR teams, the finding has direct implications for post-surgical surveillance standards and long-term burden modeling. The absence of a biologic therapy effect is itself a signal: it suggests that surveillance frameworks, not treatment intensification, may be the appropriate strategic response. 

Can IBD patients safely use GLP-1 receptor agonists for weight loss?

For medical affairs and market access teams

Obesity is an increasingly prevalent comorbidity in IBD, and GLP-1 receptor agonists are the dominant weight-loss tool in clinical practice. Without large-scale RWD in this population, prescriber caution has been difficult to counter with evidence. 

A study of 47,424 adults with both IBD and obesity found that semaglutide produced comparable weight loss to non-IBD populations, outperformed liraglutide, phentermine-topiramate, bupropion-naltrexone, and orlistat — though tirzepatide produced greater weight loss than semaglutide in the same analysis — and was not associated with increased IBD-related adverse events.  

For medical affairs and market access teams, these findings provide the real-world foundation needed to support label expansion discussions, formulary access, and patient selection frameworks in a population historically underserved by the GLP-1 evidence base. 

Do acne treatments drive IBD incidence?

For safety, regulatory, and R&D teams

The isotretinoin and IBD question has created friction in prescribing guidance and label defense for years. An analysis of more than 106 million patients between 2001 and 2022 addressed it directly. 

Three findings emerged. First, acne itself carries a modest but statistically significant association with IBD (OR 1.42; 95% CI 1.23 to 1.65); shared pathogenic pathways may explain this, opening a research question for R&D teams. Second, isotretinoin showed no association with IBD — a non-significant finding at this scale is evidence of absence, not an absence of evidence, and supports label defense and prescribing guidance directly. Third, oral tetracycline-class antibiotics used for acne also showed no association with IBD, offering the same regulatory and clinical value. Absolute risk differences were small across all associations. 

The Evidence Environment Has Changed

These five studies share a common foundation: connected, longitudinal, population-scale RWD from the TriNetX LIVE™ platform. Each answered a question that required a dataset spanning millions of patients, multiple healthcare organizations, and years of follow-up, and produced findings structured to support the regulatory submissions, market access discussions, and HEOR frameworks life sciences teams are building today. 

The most important questions in IBD research are being answered in the real world. The teams best positioned to act are the ones with access to the evidence. 

About Jeffrey Brown, PhD 

With more than 25 years of experience in research and consulting, Jeff is an internationally recognized expert in the use of RWD to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of RWD resources.